Skip to Content

Notice

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Assay for the Proteolytic Activity of Serotype A Neurotoxin From Clostridium Botulinum

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Department of the Army, DOD.

ACTION:

Notice.

SUMMARY:

In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 5,965,699 entitled “Assay for the Proteolytic Activity of Serotype A Neurotoxin from Clostridium Botulinum” issued October 12, 1999. The United States Government, as represented by the Secretary of the Army has rights in this invention.

ADDRESSES:

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

A label-based assay is described , through modifications of substrate structure and derivatization of serum albumin, which can be used to determine type A proteolytic activity without separation of products.

Start Signature

Luz D. Ortiz,

Army Federal Register Liaison Officer.

End Signature End Supplemental Information

[FR Doc. 02-12181 Filed 5-15-02; 8:45 am]

BILLING CODE 3710-08-M